• Corpus ID: 44737192

NC-531 (Neurochem).

  title={NC-531 (Neurochem).},
  author={Hugo Geerts},
  journal={Current opinion in investigational drugs},
  volume={5 1},
  • Hugo Geerts
  • Published 2004
  • Medicine
  • Current opinion in investigational drugs
NC-531 is a sulfated glycosaminoglycan mimetic that inhibits amyloid plaque formation, and is under development by Neurochem for the potential treatment of Alzheimer's disease. Phase I clinical trials of NC-531 were ongoing in November 1999, and by October 2002 phase II trials were underway. 
Inhibitors of beta-amyloid aggregation: still an issue of structure and function?
Generation of Aβ oligomerization inhibitors, rather than fibrillogenesis inhibitors, is presently considered as the drug discovery approach with the most promising therapeutic potential.
Emerging therapeutics for Alzheimer’s disease
The key pathological events in the AD brain are deposition of insoluble amyloid-β peptide, formation of neurofibrillary tangles and neuroinflammation leading, ultimately, to neuronal cell death.
New Perspectives for the Treatment of Alzheimer's Disease
The pathogenic steps leading to neurodegeneration will be discussed, together with an update of disease- modifying drugs under testing.
Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein
New, potentially disease-modifying, therapeutic approaches are targeting Aβ and tau protein, including inhibitors of glycogen synthase kinase-3 (GSK-3), the enzyme responsible for tau phosphorylation and t Tau protein aggregation inhibitors, and Therapeutic approaches directed against tau proteins, which may become a reality in the next 5 years.
Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Overall the available data suggest that the development of drugs to interfere with Abeta misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimer's disease.
Tratamento farmacológico da doença de AlzheimerTreatment of Alzheimer's Disease
The benefits and shortcomings of cholinergic replacement therapy is discussed in the light of its neurobiological, pharmacological and clinical data, illustrated by the most relevant randomised controlled trials and recent meta-analytical studies.
Design of Inhibitors of Amyloid-β Misfolding and Aggregation for Alzheimer's Therapy
The major neuropathological features of AD are synaptic and neuronal degeneration and presence of two different protein deposits: amyloid plaques and neurofibrillary tangles (NFTs), believed to play critical roles in AD neurodegenerative process.
Transglutaminases Derived from Astrocytes Accelerate Amyloid β Aggregation
The results suggest that astrocytes could uptake Aβ monomer to eliminate from brain; however, TGs derived from astroCytes might accelerate Aβ aggregation and the aggregated Aβ might enhance TG2 in astroicytes as a vicious cycle in pathological conditions.
Pharmacotherapeutic targets in Alzheimer's disease
The metal hypothesis of AD is investigated, which suggests that metal‐protein attenuating compounds may be an important component of the immune response to AD.
Amyloid imaging in vivo: implications for Alzheimer's disease management.
  • N. Verhoeff
  • Medicine
    Expert opinion on medical diagnostics
  • 2007
The prevalence of Alzheimer's disease among other dementias, the Aβ cascade, various Aβ positron emission tomography tracers that are being developed, and the potential application of these tracers for Aβ modification therapies are reviewed.